Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.47 |
| ▸ | TNF | P01375 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | IL1B | P01584 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.39 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.39 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072368 | 0.90 | CRBN (0.63) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL14072351 | 0.88 | CRBN (0.46) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186459 | 0.88 | CRBN (0.50) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186457 | 0.87 | CRBN (0.47) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186462 | 0.87 | CRBN (0.49) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186460 | 0.87 | CRBN (0.47) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186463 | 0.86 | CRBN (0.46) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186455 | 0.85 | CRBN (0.46) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186472 | 0.85 | CRBN (0.49) | CRBNCSNK1A1IKZF1IKZF3TNF | |
| SCHEMBL16186456 | 0.84 | MAP1LC3B (0.46) | CRBNCSNK1A1IKZF1IKZF3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885CSNK1A1 728/4885IKZF1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.